Syndax Pharmaceuticals Financial Ratios
NASDAQ: SNDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Syndax Pharmaceuticals ratio analysis
Syndax Pharmaceuticals earned a net margin of -165.6% in FY 2025, up from -1346.1% a year earlier. Return on equity reached -441.6%, meaning Syndax Pharmaceuticals generated -4.42 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 5.32 versus 2.34 the year before, and the current ratio was 4.40.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Syndax Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | — | 47.59 | — | — | — | — | — |
| Price / sales | 10.71 | 51.96 | — | — | 8.16 | 605.60 | 173.46 | 82.62 | 87.26 | 85.92 |
| Price / book | 28.55 | 4.27 | 2.74 | 3.31 | 2.79 | 3.64 | 8.33 | 2.36 | 1.76 | 1.25 |
| Operating margin | -158.4% | -1,434.4% | — | — | 18.8% | -4,708.2% | -3,792.9% | -5,001.7% | -2,939.0% | -3,587.4% |
| Net margin | -165.6% | -1,346.1% | — | — | 17.8% | -4,822.5% | -3,694.6% | -4,875.5% | -2,884.3% | -3,645.2% |
| Free cash flow margin | -187.5% | -1,160.9% | — | — | 20.8% | -4,697.4% | -3,336.3% | -4,529.9% | -2,251.2% | -2,903.1% |
| Return on equity (ROE) | -441.6% | -110.6% | -37.8% | -31.9% | 6.1% | -29.0% | -177.4% | -139.4% | -58.3% | -52.9% |
| Return on assets (ROA) | -53.9% | -44.0% | -34.2% | -30.0% | 5.5% | -24.3% | -88.2% | -88.1% | -44.3% | -40.8% |
| Debt / equity | 5.32 | 2.34 | 0.00 | — | — | — | — | — | — | — |
| Current ratio | 4.40 | 5.82 | 10.00 | 16.85 | 21.68 | 15.84 | 3.39 | 5.18 | 8.45 | 10.47 |
| Revenue growth | 627.8% | — | — | -100.0% | 9,109.6% | 0.0% | 0.0% | -28.0% | 72.8% | 94.6% |
| EPS growth | — | — | — | -634.8% | — | — | — | — | — | — |